Cromos Pharma

07/23/2024

In the fast-paced biotech industry, smaller CROs are gaining traction over their larger counterparts due to their ability to offer personalized services and agile responses to complex challenges. This shift is supported by market trends and the growing preference among biotech firms for more flexible and focused partnerships. The article delves into how companies like Cromos Pharma are not only competing but excelling by providing innovative solutions such as the "No Patients - No Payment" model.

For an in-depth look at the advantages of smaller CROs and their impact on biotech success, you can find more details in the article: https://cromospharma.com/unleashing-biotech-success-why-smaller-cros-are-the-key-to-big-wins/

07/18/2024

Expanding Horizons: Syngene-Cromos Pharma Alliance Transforms Clinical Research 🤝

We're thrilled to announce our strategic alliance with Syngene International Limited! This partnership combines our expertise in offering high-quality ex*****on and global coverage for clinical trials.

Together, we simplify patient recruitment across the US, Europe, and India, while providing comprehensive clinical development services. Superior project management ensures seamless ex*****on of global trials and unified project updates.

07/16/2024

Explore how integrating PMBoK, ISO 9001, and ICH GCP enhances clinical trial management and compliance. These standards provide a comprehensive framework for project management, quality assurance, and regulatory adherence, ensuring high-quality clinical research.

Learn more about their collaborative benefits in the full article: https://cromospharma.com/pmbok-iso-9001-and-ich-gcp-three-pillars-of-quality-in-clinical-research/

07/12/2024

Happy Bastille Day from Cromos Pharma! 🎉
We join in celebrating French culture and history. Enjoy the festivities and have a wonderful day!

07/09/2024

In our new edition of the MONTHLY NEWSLETTER, Cromos Pharma's Clinical Research Focus, you will find out about:

– Key Takeaways From The 2024 ASCO Annual Meeting;
– Significant Breakthrough in Epilepsy Treatment with Amber Therapeutics' Device;
– CEO Insights Podcast: Interview with Vlad Bogin (MD, FACP), Cromos Pharma's CEO;

and more in the Jule 2024 edition here: https://cromospharma.com/clinical-research-focus-30th-edition/

07/04/2024

Happy 4th of July from all of us at Cromos Pharma!

As we celebrate Independence Day, we reflect on the values of freedom and innovation that inspire our work every day.
Wishing everyone a safe and joyous holiday filled with celebration and happiness.

07/02/2024

Discover the pivotal updates in clinical trial practices with the introduction of the ICH GCP E6 R3 guidelines, effective from October 2024. This comprehensive review covers the essential changes from the enhanced flexibility in data management to the integration of new technologies and methodologies.

Learn more about how these developments aim to improve the efficacy, safety, and inclusivity of clinical trials: https://cromospharma.com/major-enhancements-set-to-transform-clinical-trial-practices-with-ich-gcp-e6-r3/

06/27/2024

Exciting news! Vlad Bogin, MD, FACP, CEO Cromos Pharma, recently joined Vitaly Geyman on the CEO Insights Podcast. In this compelling interview, Vlad delves into the dynamic nature of the pharmaceutical industry, offering his perspectives on managing a global contract research organization. He also explores the latest technological advancements in clinical trials and shares effective strategies for keeping a team motivated and efficient.

🔗 Watch the full interview to gain a deeper understanding of the pharmaceutical landscape and discover how Cromos Pharma is navigating its challenges and opportunities: https://youtu.be/WlPKhx8JSsM

06/24/2024

MAIA Biotechnology and Cromos Pharma have partnered up in an innovative collaboration to advance cancer treatment. Mutual collaborative efforts are focused on THIO, a groundbreaking telomere-targeting agent for non-small cell lung cancer (NSCLC). In a trial presented at ASCO 2024, THIO demonstrated an impressive 85% disease control rate.

Read more in the press release:https://www.pr.com/press-release/914337

06/20/2024

The concept of digital twins, a staple in industries like manufacturing and aerospace, is now making its way into the realm of clinical research. This technology involves creating a virtual replica of a physical entity—in this case, a patient or a biological process—which can then be used to simulate and predict outcomes without direct experimentation. For biotech professionals, digital twins hold the promise of transforming clinical trials, enhancing study safety, and optimizing therapeutic development.

This article explores the potential of digital twins in clinical research, reviews their current state of development, and discusses the existing limitations.

Read more:https://cromospharma.com/digital-twins-in-clinical-research-revolutionizing-study-design/

06/18/2024

The FDA has released a significant update affecting several areas, including modified plants, animals, microorganisms, human drugs, biologics, medical devices, and cross-cutting issues. They have developed a comprehensive plan to streamline and clarify regulations and oversight for biotechnology products. Of particular interest to us is the guidance related to clinical trials, focusing on human genome editing products.

Here’s a detailed look at the changes:https://cromospharma.com/fda-s-comprehensive-new-guidelines-impacting-clinical-trials-and-gene-therapy/

06/13/2024

The 2024 ASCO Annual Meeting has yet again established itself as a key event in the oncology community, bringing to light significant breakthroughs in medical science.

Vlad Bogin, MD, FACP, CEO of Cromos Pharma, has meticulously prepared a summary of the conference, showcasing the innovative research and clinical advancements that promise to revolutionize cancer treatment and patient care. The meeting featured a comprehensive range of studies across various types of cancer and treatment methods. The summary, however, selectively focuses on three primary areas: hematologic malignancies, solid malignancies, and patient care.

For a detailed exploration of these transformative discoveries read the full article here: https://cromospharma.com/key-takeaways-from-the-2024-asco-annual-meeting/

06/12/2024

In accordance with the Decision of the European Parliament and the Council of the EU establishing the Second Program of Action in the Field of Health, the EU Council Recommendation on Action in the Field of Rare Diseases was issued. This recommendation urges member states to establish and implement plans for rare diseases.

The National Plan for Rare Diseases will be instrumental in ensuring sustainable implementation of health policies that cater to the needs of patients with rare diseases, introducing systemic solutions to their health and social challenges.

We are pleased to announce that Agnieszka Milewska-Kranc, Cromos Pharma’s Head for Poland, is a vital member of this working group. On June 5, 2024, she participated in the meeting of the Parliamentary Group for Rare Diseases and the Parliamentary Group for Children, chaired by Prof. Dr. hab. n. med. Alicja Chybicka.

The meeting was dedicated to hearing representatives of patient organizations and discussing the most urgent problems and needs of people with rare diseases. Topics included access to diagnosis, treatment, rehabilitation, care, education, legal support, and social services.

Key stakeholders such as representatives from the Ministry of Health, the Ministry of Education, the Ministry of Family, Labor and Social Policy, the National Health Fund, and AOTMiT also attended the meeting.

06/11/2024

In our new edition of the MONTHLY NEWSLETTER, Cromos Pharma's Clinical Research Focus, you will find out about:

– Deep dive into Clinical Trials Specifics in Türkiye
– FDA Clarifies Distinctions in Device Remanufacturing and Maintenance in New Guidance
– Ukraine Strives to Remain a Hub for Clinical Trials Despite Conflict

and more in the June 2024 edition here: https://cromospharma.com/clinical-research-focus-29th-edition/

06/06/2024

Cromos Pharma’s US Business Development Director Nicole Brenna is currently attending the BIO Convention Conference 2024. She is actively representing our company, meeting with partners, and conducting strategic client meetings.

We look forward to fostering new connections and exploring innovative opportunities in the industry.

06/04/2024

Cromos Pharma is currently seeking a Training manager
for our team.

Location: Eastern Europe

For additional details, kindly explore our website: https://cromospharma.com/training-manager/

If you're prepared to embark on your career with Cromos Pharma, please submit your CV to [email protected]

05/30/2024

Cromos Pharma’s US Business Development Director Nicole Brenna is excited to participate in the BIO International Convention, set for June 3-6, 2024, at the Convention Center in San Diego, California.

This event consistently features insightful presentations from top pharma and biotech leaders. We are eager to share our expertise in clinical trial management and discuss how our solutions can expedite the drug development process.

To arrange a meeting and discuss your clinical programs, please contact us at [email protected]

05/27/2024

The CEO of Cromos Pharma, Vlad Bogin, MD, FACP, is attending the ASCO Conference, scheduled from May 31 to June 4 in Chicago, IL.

This prestigious event gathers leading professionals in oncology, and Dr. Bogin is eager to engage with peers, share insights, and explore the latest innovations in cancer treatment and research.

To schedule a meeting with Dr. Bogin during the conference or to learn more about our capabilities, please reach out to us at [email protected].

05/20/2024

Today, May 20th, is Clinical Trials Day, a time to honor the vital role of clinical research in advancing medical science. This year, we're highlighting some of the most unconventional and surprising studies from recent years.

From Microsoft's use of video games to improve cognitive function in older adults to Apple's wearables monitoring Parkinson's disease progression, to VR technology treating PTSD—these innovative studies show that thinking outside the box can lead to groundbreaking discoveries.

Read the full article to learn more about these fascinating clinical trials and how they are pushing the boundaries of science and medicine.

https://cromospharma.com/clinical-trials-day-2024/

05/16/2024

Cromos Pharma is currently seeking a Senior Clinical Research Associate for our team.

Location: Türkiye

For additional details, kindly explore our website: https://cromospharma.com/senior-clinical-research-associate-turkiye/

If you're prepared to embark on your career with Cromos Pharma, please submit your CV to [email protected].

05/14/2024

Türkiye is becoming an attractive destination for clinical trials due to its robust healthcare infrastructure and a large pool of treatment-naive patients.

In our latest video interview, CEO of Cromos Pharma, Vlad Bogin, MD, FACP, speaks with Seniz Sagol, the Country Head of Cromos Pharma in Türkiye. They explore why Türkiye is emerging as a biotech hub, discussing the clinical trial landscape, regulatory environment, quality and safety measures, patient recruitment, and best practices for successful trials.

Discover why Türkiye should be considered for the next clinical research venture: https://youtu.be/wm2PYZ_Tspo

Türkiye is becoming an attractive destination for clinical trials due to its robust healthcare infrastructure and a large pool of treatment-naive patients. I...

05/09/2024

We are thrilled to share that Seniz Sagol, Cromos Pharma’s Country Head for Türkiye, represented our team as a speaker at a prominent industry event in Istanbul this week. The one-day GCP Training, accredited by the Ministry of Health, was a collaborative effort alongside Memorial Hospital Group, the Association of Research-Based Pharmaceutical Companies (AIFD), and Uskudar University.

This event offered Cromos Pharma an exceptional platform to engage with a broad spectrum of stakeholders, including regulatory authorities, physicians, and industry leaders. Seniz delivered an impactful presentation on “Quality Control and Quality Assurance in Clinical Research,” emphasizing Cromos Pharma’s steadfast dedication to maintaining the highest standards in our field.

The training sessions, led by esteemed hospital directors, regulatory authorities, principal investigators, and key opinion leaders, were both diverse and informative. This event is particularly significant as it highlights the dynamic evolution of clinical research in Türkiye—a rapidly growing emerging market benefiting from advancements in the healthcare system and regulatory reforms. These developments are not only boosting research activities but also continuously improving the professional skills of those involved in the sector.

05/08/2024

In our new edition of the MONTHLY NEWSLETTER, Cromos Pharma's Clinical Research Focus, you will find out about:

– Anticipating ASCO: Key Trends in Oncology Clinical Research
– FDA Approves New Antibiotic Zevtera for Serious Bacterial Infections
– Promising Results for Prasinezumab in Early-Stage Parkinson’s Disease

and more in the May 2024 edition here: https://cromospharma.com/clinical-research-focus-28th-edition/

05/07/2024

In the last couple of decades Ukraine had established itself as a thriving hub for clinical trials, especially recognized for its advancements in oncology research. Before the conflict began, the country was a beacon for international medical research, attracting increasing number of studies each year. However, the onset of the war significantly slowed this activity, with the number of new trials plummeting from around 300 annually to just 9 in 2022.

Read more in the article: https://cromospharma.com/clinical-trials-in-ukraine-2024/

05/02/2024

Cromos Pharma’s US Business Development Director, Nicole Brenna, is delighted to participate in the BIO International Convention, scheduled for June 3-6, 2024, at the San Diego Convention Center, California.

This prestigious event continues to be a highlight, featuring presentations from leading figures in the pharma and biotech sectors. Nicole is eager to share how Cromos Pharma's extensive expertise in managing all aspects of clinical trials and our innovative solutions can accelerate the drug development process.

Please contact us at [email protected] to arrange a meeting to discuss your clinical programs in more detail.



04/30/2024

The ASCO Conference, a pivotal event in the world of oncology, is fast approaching. Known for bringing together leading experts to discuss groundbreaking developments in cancer research and treatment, ASCO is a cornerstone for innovation and collaboration in the field.

In anticipation of this event, Cromos Pharma's CEO, Vlad Bogin is preparing to attend and share his expert insights. Dr. Bogin's article offers a fresh perspective on modern clinical research in oncology, highlighting innovative approaches and future trends.

Read more in Cromos Pharma's CEO Vlad Bogin, MD, FACP new article: https://cromospharma.com/anticipating-asco-key-trends-in-oncology-clinical-research/

04/25/2024

Last week, Cromos Pharma US executive team gathered in Miami for a full-day strategy session. This meeting was aimed at reinforcing our collaborative spirit and refining our business approaches. More than just a conventional meeting, it was a great chance for our team members to build stronger bonds and share important ideas.

We wrapped up the day with a fun team-building activity, which was a great way to end our busy schedule. We also enjoyed some downtime, taking in the beautiful sights of vibrant Miami. Here are a couple of photos of us experiencing the lively atmosphere of Miami, a nice finish to a productive day.

04/24/2024

We are delighted to announce that Nicole Brenna, our Director of US Business Development, will be attending the BioNJ's BioPartnering Conference, which is scheduled for May 14, 2024, in Jersey City, NJ.

Nicole looks forward to connecting with potential partners and clients to gain a deeper insight into their clinical development projects.

If you are interested in setting up a meeting to discuss your forthcoming clinical trials, please do not hesitate to reach out to us at [email protected].

04/22/2024

Wishing a joyful Passover to all from Cromos Pharma!

May this season bring peace and happiness to your homes. We value the strength and community spirit Passover embodies.

Chag Sameach! ✨

04/18/2024

Last week, the Cromos Pharma Poland executive team gathered in Warsaw for a dynamic full-day meeting, marking a significant step in strengthening our internal connections and enhancing operational strategies. This gathering was not just a meeting but an opportunity for team members to forge stronger bonds and share insights.

The agenda was packed with constructive discussions aimed at refining our existing processes and exploring potential avenues for expanding our operations within Poland. The day was also fruitful in discussing ongoing and planned studies, highlighting our commitment to growth and innovation.